| Identification | Back Directory | [Name]
Pyrazolo[1,5-a]pyrazine-2-carboxylic acid, 4,5-dihydro-6-[1-[(4-methoxyphenyl)methyl]-1H-pyrazol-4-yl]-4-oxo-, methyl ester | [CAS]
2127110-22-7 | [Synonyms]
JAK-IN-25
Pyrazolo[1,5-a]pyrazine-2-carboxylic acid, 4,5-dihydro-6-[1-[(4-methoxyphenyl)methyl]-1H-pyrazol-4-yl]-4-oxo-, methyl ester | [Molecular Formula]
C19H17N5O4 | [MOL File]
2127110-22-7.mol | [Molecular Weight]
379.37 |
| Chemical Properties | Back Directory | [Boiling point ]
624.6±55.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
10.39±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM. JAK-IN-25 has the potential for cancer research[1]. | [IC 50]
Tyk2: 6 nM (IC50); JAK1: 21 nM (IC50); JAK2: 8 nM (IC50); JAK3: 1051 nM (IC50) | [References]
[1] Matthew Frank Brown, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. US20230045252A1. |
|
|